Select Publications

Bukowski RM et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-41. Abstract

Escudier B et al; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11. Abstract

Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24. Abstract

Rini BI et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Proc ASCO Genitourinary Cancers Symposium 2008;Abstract 350.

Yang JC et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34. Abstract

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Home

Editor
Neil Love, MD

Interviews

Robert J Motzer, MD
- Select publications

Daniel J George, MD
- Select publications

Robert J Amato, DO
- Select publications

Janice P Dutcher, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office